Systematic Analysis of Gene Expression Alterations and Clinical Outcomes for Long-Chain Acyl-Coenzyme A Synthetase Family in Cancer

Wei-Ching Chen¹, Chih-Yang Wang¹,², Yu-Hsuan Hung¹,², Tzu-Yang Weng¹, Meng-Chi Yen³, Ming-Derg Lai¹,²,⁴ *

¹ Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan, Taiwan, R.O.C.  ² Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan, R.O.C.  ³ Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C.  ⁴ Center for Infectious Diseases and Signaling Research, College of Medicine, National Cheng Kung University, Tainan, Taiwan, R.O.C

* a1211207@mail.ncku.edu.tw

Abstract

Dysregulated lipid metabolism contributes to cancer progression. Our previous study indicates that long-chain fatty acyl-CoA synthetase (ACSL) 3 is essential for lipid upregulation induced by endoplasmic reticulum stress. In this report, we aimed to identify the role of ACSL family in cancer with systematic analysis and in vitro experiment. We explored the ACSL expression using Oncomine database to determine the gene alteration during carcinogenesis and identified the association between ACSL expression and the survival of cancer patient using PrognoScan database. ACSL1 may play a potential oncogenic role in colorectal and breast cancer and play a potential tumor suppressor role in lung cancer. Co-expression analysis revealed that ACSL1 was coexpressed with MYBPH, PTTPRE, PKFB3, SOCS3 in colon cancer and with LRRFIP1, TSC22D1 in lung cancer. In accordance with PrognoScan analysis, downregulation of ACSL1 in colon and breast cancer cell line inhibited proliferation, migration, and anchorage-independent growth. In contrast, increase of oncogenic property was observed in lung cancer cell line by attenuating ACSL1. High ACSL3 expression predicted a better prognosis in ovarian cancer; in contrast, high ACSL3 predicted a worse prognosis in melanoma. ACSL3 was coexpressed with SNUPN, TRIP13, and SEMA5A in melanoma. High expression of ACSL4 predicted a worse prognosis in colorectal cancer, but predicted better prognosis in breast, brain and lung cancers. ACSL5 was coexpressed with TMEM140, TAPBPL, BIRC3, PTTPRE, and SERPINB1. Low ACSL6 predicted a worse prognosis in acute myeloid leukemia. ACSL6 was coexpressed with SOX6 and DARC. Altogether, different members of ACSLs are implicated in diverse types of cancer development. ACSL-coexpressed molecules may be used to further investigate the role of ACSL family in individual type of cancers.
Introduction

Cancer is a leading cause of death worldwide. Many physiological conditions, such as hypoxia, reactive oxygen species (ROS) and metabolic dysfunction, contribute to the cancer progression [1–3]. Fatty acids are important fuel for cell growth and are essential components of cell membranes. Altered fatty acid has been observed in varieties of cancers and is recognized as a marker of cancer. Cancer cell with altered lipid metabolism exhibits the increase of proliferation, progression and metastasis [4]. The elevated de novo fatty acid synthesis is used to meet the energy demand and sustains additional cellular process. Overexpression of fatty acid synthase (FASN) in breast and prostate cancer is associated with the poor prognosis and inhibition of FASN attenuates the lipogenesis and serves as the therapeutic approach [5]. Transcriptomic analysis of metabolite reveals the expression pattern of lipid-associated gene in cancers [6,7].

Fatty acid synthesis starts with the carboxylation of acetyl-CoA to malonyl-CoA via acetyl-CoA carboxylase. The formation of malonyl-CoA provides the 2-carbon donor for fatty acid chain synthesis. Free fatty acid is converted to fatty acyl-CoA by acyl coenzyme A synthetase in an ATP-dependent manner and the unit of fatty acyl-CoA leads to multiple physiological responses and metabolic processes, such as membrane phospholipid biosynthesis, energy usage and storage, and signal lipids [8]. There are five members of acyl coenzyme A synthetase family, including short-chain acyl-CoA synthetases, medium-chain acyl-CoA synthetases, long-chain acyl-CoA synthetases (ACSL), bubblegum acyl-CoA synthetases, and very long-chain acyl-CoA synthetases. Each of the members has unique substrate preference and enzyme activity in different cellular locations. The long-chain acyl-CoA synthetase (ACSL) prefers the specific substrate of fatty acid with the chain lengths of 12 to 20 carbon atoms [9]. The five isoforms of ACSLs in mammalian are identified as the ACSL1, 3, 4, 5, and 6 [10]. The ACSL1 is abundantly expressed in lipid droplet, microsome and mitochondria and responsible for the elevated levels of the unsaturated fatty acids oleate and linoleate [11]. ACSL3 is present in brain and shows preference for myristate, arachidonate and eicosapentaenoate. ACSL4 favorably utilizes arachidonate as substrate. ACSL5 has a marked preference for palmitic acid, palmitoleic acid, oleic acid and linoleic acid. ACSL6 is found in plasma membrane and displays a high activity with fatty acid with C16-C20 saturated and polyunsaturated [12]. ACSL is the response gene for PPARγ which mediates the lipid metabolism and regulates the caloric absorption [13]. Oncostatin–mediated reduction of plasma LDL-C and total cholesterol is regulated by ACSL3 and ACSL5 [14]. In our previous study, ACSL3 is involved in the endoplasmic reticulum stress-induced lipid accumulation via GSK-3-β. The inhibition of ACSL3 by ACSL inhibitor or GSK-3-β inhibitor reduces the lipid accumulation in liver cell [15]. The increased ACSL3 in U87 human glioblastoma cell drives the tumorigenesis, whereas ACSL3 knockdown reduces lung cancer cell growth [16,17]. In contrast, ACSL3 is decreased in high-grade and metastatic prostate cancer [18]. ACSLs may function in diverse roles in different cancers, indicating the importance of having a comprehensive analysis of ACSL in cancers. Nevertheless, there is no holistic investigation to explore ACSL expression in various types of cancer.

Several databases assessing the gene expression signature of clinical cancer tissue by microarray analysis were established. Oncomine platform includes more than 700 independent datasets with nearly 90,000 microarray experiments. The database identifies the gene expression signature in nearly every pathology-based subtype of cancers [19,20]. The differential expression pattern implies the potential oncogenic role or tumor suppressor role in cancer and leads to a reliable hypothesis for cancer research [21]. We have previously performed a meta-analysis on public microarray datasets and demonstrate voltage-gated calcium gene signatures in clinical cancer patients [22]. Therefore, we aimed to systematically analyze the ACSL expression...
and identify the survival of cancer patients with high or low ACSL expression from the Onco-
mime and PrognoScan database, respectively. The co-expression analysis reveals the biological
function and provides the information for the possible underlying mechanism. The gene ontol-
ogy enrichment is performed to predict the gene function and regulation pattern [23]. In this
report, we identified the co-expression profiles of each ACSL isoform from the Oncomine data-
base and performed GeneGo Metacore analysis to unveil the biological function. The analyses
demonstrate the significance of each ACSL isoform in tumor formation of various kinds of
cancer and the association of expression level with survival of cancer patient. Furthermore, the
*in vitro* data supports the experimental evidence for a set of accurate prediction from online
database, having a better understanding of ACSL in cancers. To our best knowledge, this is the
first systematic analysis indicating the role of ACSL family in cancer progression.

**Material and Method**

**Oncomine database analysis**

The expression of ACSL family members in various types of cancers was identified from Onco-
mine database using the analysis of “Gene summary view” and “Dataset view” (https://www.
oncomine.org/resource/login.html) [19,20]. The mRNA expression fold in cancer tissue com-
pared to the normal tissue was obtained as the parameters of p-value < 1E-4, fold change > 2,
and gene ranking in the top 10% and the analyses were summarized in S1, S3, S5, S7 and S9
Tables. Co-expression analysis in Oncomine was used to identify sets of genes with synchro-
nous expression patterns. The co-expression profiles of ACSL isoforms in different types of
cancers were identified and presented as the pattern of heat map.

**Prognoscan database analysis**

PrognoScan includes public microarray datasets with clinical annotation of gene expression
and prognosis from Gene Expression Omnibus (GEO), ArrayExpress and individual labora-
tory web sites. The correlation between ACSL expression and survival in various types of can-
cers was analyzed by PrognoScan database (http://www.abren.net/PrognoScan/) [24]. The
threshold was adjusted to cox p-value < 0.05 and the analyses were summarized in S2, S4, S6, S8
and S10 Tables.

**Kaplan-Meier plotter database analysis**

A Kaplan-Meier plotter database contains the 4,142 breast, 1,648 ovarian, 2,437 lung and 1,065
gastric cancer patients using probe sets on the HGU133 Plus 2.0 array. The correlation between
ACSL expression and survival in breast, ovarian and lung was analyzed by Kaplan-Meier plot-
ter (http://kmplot.com/analysis/) [25]. The hazard ratio with 95% confidence intervals and log
rank p-value was also computed.

**GeneGo Metacore analysis**

The function analysis was performed by GeneGo Metacore software using the GO Processes.
We applied the co-expression profiles from the Oncomine as the parameter of correlation > 0.6
and the top ten GO Processes were identified.

**Cell line**

The HCT116 was obtained from Dr. H.L. Wu at National Cheng Kung University. The MDA-
MB-231 was obtained from Dr. P.L Kuo at Kaohsiung Medical University. The A549 was
obtained from Dr. W.T. Chang at National Cheng Kung University.
RNA interference and lentivirus production

ACSL1 shRNAs were obtained from the National RNai Core facility (Academia Sinica, Taipei, Taiwan). The following target sequences were used: GCCCAGATGATACTTTGATAT and CCCTTGGTGTATTTCTATGAT. The Turbofect transfection reagent was used for production of lentiviral particles according to the protocol provided from the National RNai Core facility.

Western blotting analysis

Cell lysate was harvested in RIPA lysis buffer and the amount of protein was determined with Micro BCA Protein Assay kit (Millipore, MA, USA). 30μg protein lysate was loaded into acrylamide gels and then transferred onto polyvinylidene fluoride membranes (Amersham Biosciences, Piscataway, NJ). The membrane was blocked with 5% nonfat dry milk and incubated with primary antibody for specific protein overnight. The membranes were incubated with horseradish peroxidase-conjugated secondary antibody and probed with ECL western blotting detection system (Millipore, MA, USA) and visualized with the BioSpectrum AC imaging system. The catalog number of antibody was as the following: the anti-ACSL1 antibody (#4047, Cell Signaling) and the anti-β-actin antibody (GTX109639, GeneTex).

MTT assay

The cells were seeded onto 24 well plate at the density of 2X10^4 per well. The cells were incubated with MTT (Thiazolyl Blue Tetrazolium Bromide, Sigma Chemical) for 3 hours at the 5% CO_2 and 37°C and the absorbance was detected at 570 nm by ELISA reader.

Boyden chamber assay

The upper wells of the chamber were seeded at the density of 2.6X10^4 cells in serum-free DMEM, while lower wells contained the DMEM with 10% FBS. The cells of HCT116, A549 and MDA-MB-231 were incubated for 48, 24 and 6 hours, respectively. The cells that migrated through the polycarbonate filer were fixed using methanol and stained with Giemsa stain. The stained cell images were taken under the 10X objective lens by microscope and the mean number of stained cell was counted in five fields.

Anchorage-independent growth

5X10^3 cells were suspended in the 0.3% agar over a layer of 0.6% agar and incubated for 14 days in a 5% CO_2 atmosphere humidified incubator at 37°C. The colonies were stained with 0.05% crystal violet. The colony images were taken under the 4X objective lens by microscope and the mean area of stained colony was quantified in ten fields by the Image-Pro Plus software.

Statistical analysis

All statistical analyses were performed using GraphPad Prism version 4 (GraphPad Software, La Jolla, CA, USA). The statistical analysis was performed using two-way ANOVA followed by Bonferroni post-tests for MTT assay and one-way ANOVA followed by Tukey post hoc for migration and soft agar assay.

Result

ACSL contributes to the different physiological roles in various types of cancers [12]. ACSL1 modulates the uptake of fatty acid in hepatoma cells [26]. Hepatocytic deletion of Pten in mice
develops hepatocellular carcinoma and increased acsl5:acsl1 ratio [27]. To elucidate the role of ACSL family in cancer, the systematic analysis of ACSL family expression was demonstrated using Oncomine database. The expression of ACSL family was compared between tumor and normal tissues in different types of cancers. The threshold was designed as the following parameters: p-value of 1E-4, fold change of 2, and top gene ranking of 10%. The ACSL expression was higher in cancer than that in normal tissue in certain types of cancers. On the other hand, ACSL expression was lower in cancer than that in normal tissue in other types of cancers. These data indicates that individual ACSL may play either oncogenic or anti-oncogenic function depending on the cancer types (Fig 1). Therefore, detailed analysis of ACSL1, ACSL3, ACSL4, ACSL5, and ACSL6 were described below.

ACSL1

ACSL1 is associated with glucose homeostasis. The activation of ACSL1 regulates the insulin resistance by PKC activation in muscle cell [28,29]. ACSL1 interacts with the fatty acid transport protein (FATP), which is able to facilitate the uptake of fatty acid [30]. The activation of acyl-CoA-synthetase by ACSL1 promotes the fatty acid accumulation, indicating the potential target for hepatic steatosis [26,31]. Loss of ACSL1 favors the ABCA1 expression, contributing to the apoA-I-mediated cholesterol efflux in macrophage [11]. Lacking ACSL1 in heart-specific tissue drives the reduction of β-oxidation and results in the heart dysfunction [32]. In addition, miR-205 blocks the lipogenesis in liver cancer and anti-miR-205 promotes the increase of triglyceride by ACSL1. The negative correlation of miR-205 and ACSL1 expression in hepatitis B virus X protein (HBx)-transgenic mice suggests that miR-205 leads to the dysregulation of lipid metabolism by ACSL1 and the cancer progression [33]. We applied Oncomine database to identify the ACSL1 expression in various kinds of cancer with the thresholds mentioned above. ACSL1 was upregulated in colorectal cancer, but decreased in lung and breast cancer (Fig 2A–2C). In addition, there was a lower expression level of ACSL1 in brain, cervical, esophageal, head and neck, leukemia, liver, and sarcoma cancers (Fig 2D and S1 Table). To further elucidate the role of ACSL1 in cancer progression, the prognostic value of ACSL1 expression in bladder, brain, breast, colorectal and ovarian cancer patients was determined using PrognoScan database according to the parameter of cox p-value <0.05 (Fig 2E and S2 Table). The breast and colorectal cancer patients with higher ACSL1 expression has poor survival (Fig 2F and 2G). We further used the Kaplan-Meier plotter database to evaluate the survival of breast and lung cancer patients. The probe 201963 for ACSL1 was used in analyzing the prognostic value in breast cancer and lung cancer patients. These data indicated that ACSL1 was associated with the poor survival in breast cancer, but was associated with the better survival in lung cancer (Fig 2H and 2I). The co-expression analysis reveals the biological function and provides the information for studying the underlying mechanism. We identified the co-expression profile of ACSL1 from the Oncomine database (S1A–S1C Fig). We further applied GeneGo Metacore to annotate gene ontology. No genes with the correlation > 0.6 were found in breast cancer dataset (S1A Fig). Specifically, the co-expression profiles for ACSL1 with a strong cluster of 126 genes (R > 0.6) across a panel of 65 rectal adenocarcinoma and 65 normal colorectal samples and 878 genes (R > 0.6) across a panel of 186 lung cancer and 17 normal lung samples were uploaded and the top ten GO Processes were listed (S1D and S1E Fig). In colorectal cancer, ACSL1 was coexpressed with myosin binding protein H (MYBPH), protein tyrosine phosphatase, receptor type E (PTPRE), 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), suppressor of cytokine signaling 3 (SOCS3), leukocyte immunoglobulin like receptors (LILRA3), and chemokine (C-C motif) ligand 4 (CCL4). These molecules mainly influence immune response, metabolism, and chemotaxis. As for lung cancer, ACSL1 was coexpressed
with leucine rich repeat (in FLII) interacting protein 1 (LRRFIP1) and TSC22 domain family member 1 (TSC22D1). The analysis revealed that ACSL1 may be involved in immune response and cell chemotaxis in colorectal cancer and response to stress in lung cancer. Combination of the gene expression analysis from Oncomine and survival analysis from PrognoScan or Kaplan-Meier plotter revealed the oncogenic role of ACSL1 in colorectal cancer and the tumor suppressor role for ACSL1 in lung cancer. To validate the oncogenic role of ACSL1 in colorectal cancer and tumor suppressor role in lung cancer, two different lentiviral particles expressing ACSL1 shRNA were introduced to colorectal HCT116 cell line and lung A549 cell line, respectively. The knockdown efficacy of ACSL1 was determined by western blotting (Fig 3A). ACSL1 shRNA decreased proliferation in HCT116 cells, but increased proliferation in A549 cells (Fig 3B). In addition, the anchorage-independent growth and cell migration were inhibited in HCT116 after lentiviral particles expressing ACSL1 shRNA infection. In contrast, ACSL1 shRNA enhanced the anchorage-independent growth and cell migration in

| Cancer Type          | ACSL1 | ACSL3 | ACSL4 | ACSL5 | ACSL6 |
|----------------------|-------|-------|-------|-------|-------|
| bladder cancer       | 1     | 1     |       |       |       |
| brain and CNS cancer | 1     | 3     | 1     | 4     | 2     |
| breast cancer        | 13    | 1     | 5     | 4     | 1     |
| cervical cancer      | 1     | 2     | 4     | 13    | 1     |
| colorectal cancer    | 1     | 2     | 4     |       | 13    |
| esophageal cancer    | 1     |       |       |       | 1     |
| gastric cancer       |       |       |       |       |       |
| head and neck cancer | 2     | 1     | 2     |       |       |
| kidney cancer        |       | 2     |       |       | 4     |
| leukemia             | 8     |       |       |       | 5     |
| liver cancer         | 4     | 1     | 6     |       | 2     |
| lung cancer          | 1     |       |       | 4     | 1     |
| lymphoma             |       | 1     | 4     |       | 2     |
| melanoma             |       | 1     |       |       |       |
| myeloma              |       |       | 1     |       |       |
| other cancer         | 1     | 1     |       |       | 1     |
| ovarian cancer       |       |       | 1     |       |       |
| pancreatic cancer    | 1     |       |       |       |       |
| prostate cancer      |       | 1     |       |       |       |
| sarcoma              |       |       | 1     |       |       |
| significant unique analyses | 3 | 1 | 4 | 5 | 20 | 18 | 6 | 9 | 13 | 15 |
| total unique analyses | 446 | 425 | 366 | 366 | 414 |

Fig 1. ACSL mRNA expression in various cancer types. The comparison indicated the number of datasets with ACSL mRNA overexpression (right column, red) and under expression (left column, blue) in cancer versus normal tissue. The threshold was designed with following parameters: p-value of 1E-4, fold change of 2, and gene ranking of 10%.

doi:10.1371/journal.pone.0155660.g001
Fig 2. ACSL1 analysis in different cancer types. The box plot comparing specific ACSL1 expression in normal (left plot) and cancer tissue (right plot) was derived from Oncomine database. The analysis was shown in breast carcinoma relative to normal breast (A), in rectal adenocarcinoma relative to normal rectum (B), and in lung carcinoma relative to normal lung (C). The fold change of ACSL1 in various types of cancers was identified from our analyses in S1 Table and expressed as the forest plot (D). The statistically significant hazard ratio in various types of cancers was identified from our analyses in S2 Table and expressed as the forest plot (E). The survival curve comparing the patient with altered expression of ACSLs predict prognosis in cancer.
A549 (Fig 3C and 3D). The bioinformatics prediction of potential role of ACSL1 from Onco-
mine and PrognoScan in colorectal and lung cancer is supported by the
in vitro
assay.

Interestingly, the data obtained from Oncomine indicated that ACSL1 may function as a
tumor suppressor gene in breast cancer (Fig 2A); however, the data obtained from PrognoScan
and Kaplan-Meier plotter indicated that ACSL1 may play a potential oncogene in breast cancer
(Fig 2F and 2I). To study the inconsistent bioinformatic results of ACSL1 in breast cancer, the
lentiviral particles containing ACSL1 shRNAs were introduced to MDA-MB-231 breast cancer
cell and the protein level of ACSL1 was determined by western blotting (Fig 3A, right panel).
ACSL1 knockdown cell exhibited a reduced cell proliferation, which was demonstrated by
MTT assay (Fig 3B, right panel). Downregulation of ACSL1 also inhibited anchorage-indepen-
dent growth and cell migration of the MDA-MB-231 cells with soft agar assay and Boyden
chamber assay (Fig 3C and 3D, right panel). Altogether, the prediction of oncogenic role of
ACSL1 from PrognoScan and Kaplan-Meier plotter in breast cancer is supported by the
in vitro
experimental assay. The
in vitro
experimental analysis may be useful to resolve the dis-
crepancy of analyses on ACSL1 obtained from Oncomine database and PrognoScan.

ACSL3

ACSL3 is abundant in lipid droplets and endoplasmic reticulum and is required for the fatty
acid uptake. N-terminus of ACSL3 is required for the translocation from the endoplasmic retic-
ulum to lipid droplet (LD) [34]. ACSL inhibitor, triacsin C, reduces ACSL3 expression and
inhibits the lipid droplet formation [35,36]. ACSL3 is responsible for the VLDL assembly,
which coordinate the lipid metabolism by exporting the exogenous cholesterol and triglyceride
into plasma and is associated with the HCV infection. The downregulation of ACSL3 by
siRNA reduces the VLDL secretion and inhibits the secretion of HCV particles from infected
hepatocyte [37]. ACSL3 promotes palmitic acid-triggered osteoblastic gene expression and cal-
cium deposition in vascular smooth muscle cell [38]. The cytokine oncostatin M-induced
ACSL3 activation is dependent upon ERK-pathway activation and is associated with the
decrease of cellular triglyceride and the increase of fatty acid β-oxidation [14]. Furthermore,
PPAR-δ is involved in the activation of cytokine oncostatin M-induced ACSL3 expression in
hepatoma [39]. The induction of ACSL3 is demonstrated by LXR, which is a nuclear protein
and involved in the lipid uptake from lipoprotein [40]. Previous study indicates that ACSL3 is
overexpressed in lung cancer [17]. In contrast, there is a lower ACSL3 expression in prostate
cancer tissue compared to that in normal tissue [18]. Our analysis revealed that ACSL3 was
down-regulated in ovarian cancer and up-regulated in melanoma (Fig 4A and 4B). In system-
atic analysis, ACSL3 was overexpressed in head-neck and liver cancer, but was underexpressed
in colorectal cancer (Fig 4C and S3 Table). The prognostic value of ACSL3 was analyzed using
the PrognoScan database with the threshold above (Fig 4D and S4 Table). The better prognosis
in ovarian cancer patient and the worse prognosis in melanoma patient with higher ACSL3
expression were in accordance with the result from Oncomine (Fig 4E and 4F). The oncogenic
role of ACSL3 in melanoma is consistent with a previous study [16]. On the other hand,
ACSL3 may be considered as a potential tumor suppressor gene in ovarian cancer develop-
ment. The co-expression profiles of ACSL3 were identified from Oncomine (Fig 4G and 4H).
We identified the co-expression profiles for ACSL3 with a strong cluster of 27 genes across a
panel of 185 ovarian carcinoma and 10 normal ovary tissues and 229 genes across a panel of 45
Fig 3. ACSL1 shRNAs modulate cancer growth in vitro. ACSL1 expression was downregulated with lentiviral particles containing shRNA targeting ACSL1 or luciferase in HCT116, A549 and MDA-MB-231. (A) The protein expression of ACSL1 was determined by western blotting with an anti-ACSL1 antibody. (B) The proliferation of the cell with ACSL1 knockdown expression was analyzed by MTT assay at the indicated time points. The statistical difference was calculated using two-way ANOVA followed by Bonferroni post-tests. * indicated p<0.05; n.s indicated not statistically significant. (C) The cell migration of the cell with ACSL1 knockdown expression was...
analyzed by Boyden chamber assay. The number of migrated cell was counted and the result was expressed as the fold change relative to the parental cell. All pairs of groups were compared using Tukey post hoc multicomparison test for one-way ANOVA. * indicated p<0.05; n.s indicated not statistically significant. (D) The cells with ACSL1 knockdown expression were plated in soft agar, and the colonies were monitored for 14 days. The colonies were quantified using Image-Pro Plus software. The result was expressed as the fold change relative to the parental cell. All pairs of groups were compared using Tukey post hoc multicomparison test for one-way ANOVA. * indicated p<0.05; n.s indicated not statistically significant.

doi:10.1371/journal.pone.0155660.g003

melanoma and 25 normal samples. GeneGo Metacore annotation for enriched biological process indicated that the genes involved in phosphatidylcholine biosynthetic process and organelle fission were more likely to be coexpressed in ovarian cancer and in melanoma, respectively (Fig 4I and 4J). It was interesting to note that ACSL3 was coexpressed with snurportin 1 (SNUPN), thyroid hormone receptor interactor 13 (TRIP13), and semaphorin 5A (SEMA5A). TRIP13 is involved in the spindle-assembly checkpoint and SNUPN is involved in snRNP importing. Semaphorin 5A (SEMA5A) is known to be responsible for certain types of autism.

ACSL4

ACSL4 is present in the peroxisome, mitochondria, and endoplasmic reticulum and is involved in arachidonate metabolism [41,42]. The deficiency of ACSL4 is correlated with the mental retardation and Alport syndrome [43]. The ACSL4-heterozygous mice have the abnormal uteri and uterine prostaglandin production [44]. ACSL4 regulates the neuron growth and differentiation [45]. Induction of ACSL4 expression promotes the tumor progression in xenograft model, and the combination of ACSL4, LOX-5 and COX-2 inhibitor effectively reduces the tumor formation in vivo [46]. The expression of ACSL4 mRNA is correlated with the estrogen receptor alpha expression and ACSL4 is sensitive to the triacsin C treatment, indicating that ACSL4 affects the steroid hormone-sensitivity in breast and prostate cancer [47]. ACSL4 catalyzes the conversion of free arachidonic acid into arachidonic acid-CoA ester and reduces the arachidonic acid-induced apoptosis in colon cancer. The overexpression of ACSL4 is associated with the colon carcinogenesis [48,49]. ACSL4 is also overexpressed in liver cancer tissues compared with the corresponding normal tissue. Arachidonic acid drives the ACSL4 ubiquitination by the substrate-induced posttranslational regulatory mechanism [50,51]. ACSL4 expression is negatively correlated with the amount of miR-205 in clinical HCC specimens. Hepatitis B virus X protein-induced lipogenesis can be abolished by miR-205 targeted ACSL4 mRNA [52]. Analysis from the Oncomine indicated that ACSL4 was down-regulated in bladder, brain, breast, leukemia, and lung cancer, but up-regulated in colorectal cancer, head and neck, kidney, myeloma, and liver cancer (Fig 5A and S5 Table). The prognostic analysis indicated that the colorectal patient with higher ACSL4 expression had poor survival; in contrast, the brain, breast, and lung cancer patient with lower ACSL4 expression had poor survival (Fig 5B and S6 Table). The analysis of ACSL4 gene expression in cancer from Oncomine (Fig 5C–5F) was in accordance with the survival analysis from PrognoScan (Fig 5G–5J). Combination of the gene expression from Oncomine and survival from PrognoScan revealed the oncogenic role of ACSL4 in colorectal cancer and the tumor suppressor role of ACSL4 in breast, brain, and lung cancer. These data are consistent with a previous study on the expression of ACSL4 in colon cancer tissues [49]. However, the results of the current analysis are inconsistent with a previous study investigating the overexpressed ACSL4 in breast cancer tissue [53]. The co-expression profiles for ACSL4 in breast, brain, colorectal and lung cancer were analyzed from Oncomine (S2A–S2D Fig). The co-expression profiles for ACSL4 were applied to annotate gene ontology using GeneGo Metacore with a strong cluster of 3,444 genes across a panel of 53 breast carcinoma and 6 normal breast samples, 117 genes across a panel of 10 brain tumor and 5 normal brain samples, 509 genes across a panel of 20 colorectal cancer and 20 normal colorectal
Fig 4. ACSL3 analysis in various cancer types. The box plot comparing specific ACSL3 expression in normal (left plot) and cancer tissue (right plot) was derived from Oncomine database. The analysis was shown in ovarian carcinoma relative to normal ovary (A) and in melanoma relative to normal skin (B). The fold change of ACSL3 in various types of cancers was identified from our analyses in Table S3 and expressed as the forest plot (C). The statistically significant hazard ratio in various types of cancers was identified from our analyses in Table S4 and expressed as the forest plot (D). The survival curve comparing the patient with high (red) and low (black) expression was plotted from PrognoScan database. The analysis of
samples, and 54 genes across a panel of 25 lung adenocarcinoma and 25 normal lung samples. The GO processes analyses demonstrated the co-expression genes, including serine protease inhibitor 2 (SERPIN2), heterogeneous nuclear ribonucleoprotein C-like 1 (HNRNPC1L1), inter-alpha-trypsin inhibitor heavy chain 2 (ITIH2), protein C receptor (PROCR), and leucine rich repeat (in FLII) interacting protein 1 (LRRFIP1). These gene products were involved in cellular metabolic process, Fc receptor signaling pathway, extracellular matrix organization, and system development in breast, brain, colorectal and lung cancer (S2E–S2H Fig). It appears that ACSL4 may have distinct roles in various tissues. The detailed mechanism by which ACSL4 modulates cancer progression need to be further investigated.

**ACSL5**

ACSL5 is located on mitochondria and involved in the enterocyte apoptosis by alternative splicing [54]. A reduced ACSL5 expression is observed in the impaired small intestinal mucosa [55]. The expression of ACSL5 functions as a marker for gastrointestinal tract differentiation and villus atrophy [56,57]. ACSL5 is present in mitochondria and regulates lipid metabolism dependent on TP53 status in colorectal adenocarcinoma [58]. The lower expression of ACSL5 is observed in the colorectal cancer tissue and the patient with the lower ACSL5 has a longer disease-free interval (DFI) [59]. The expression level of ACSL5 is reduced in the neoplastic urothelial tissues and the expression pattern of ACSL5 is associated with the differential types of urothelium [60]. ACSL5 promotes the fatty acid uptake which results in fat storage or β-oxidation in liver cancer [14,61]. Up-regulation of ACSL5 is associated with the hepatocyte steatosis and is sensitive to fatty acid-induced hepatic cell death [62]. Downregulation of ACSL5 by RNAi significantly reduced fatty acid-induced lipid droplet formation in hepatocyte [63]. However, the impairment of ACSL activity in Acsl5-KO mice is insufficient to alter the long chain fatty acid absorption [64]. A single nucleotide polymorphism of ACSL5 promoter drives the ACSL5 mRNA expression in skeletal muscle cell and induces the weight loss [65]. ACSL5 is highly expressed in glioma and drives the cell growth through midkine (MDK) in the acidic microenvironment [66]. Our analysis revealed that ACSL5 is significantly overexpressed in bladder, esophageal, lung, pancreatic and prostate cancer. A significant decrease of ACSL5 was observed in breast, liver, lung, and ovarian cancer (Fig 6A–6D and S7 Table). There was a difference between lung carcinoma and lung adenocarcinoma that lung carcinoma expressed low level of ACSL5 and lung adenocarcinoma expressed high level of ACSL5 (S7 Table). To confirm the role of ACSL5 in cancer, we analyzed the prognostic value using PrognoScan. The analysis indicated that the brain cancer patient with higher ACSL5 expression had poor survival; in contrast, the patient with higher ACSL5 expression had good survival in breast, colorectal, lung and ovarian cancer (Fig 6E–6H and S8 Table). To further confirm the survival, the Kaplan-Meier plotter was used to identify the prognostic value in breast, lung and ovarian cancer. The better prognosis in breast, lung and ovarian cancer patient with higher ACSL5 expression was in accordance with the result from Oncomine and PrognoScan database, implying the tumor suppressor role of ACSL5 in breast, lung and ovarian cancer (Fig 6I–6K). The co-expression profiles of ACSL5 were identified from the Oncomine database (S3A–S3C Fig). The co-expression profiles for ACSL5 with a strong cluster of 3 genes across a panel of 40 breast
Fig 5. ACSL4 analysis in various cancer types. The fold change of ACSL4 in various types of cancers was identified from our analyses in S5 Table and expressed as the forest plot (A). The statistically significant hazard ratio in various types of cancers was identified from our analyses in S6 Table and expressed as the forest plot (B). The box plot comparing specific ACSL4 expression in normal (left plot) and cancer tissue (right plot) was derived from Oncomine database. The analysis was shown in breast carcinoma relative to normal breast (C), in glioblastoma relative to normal brain (D), in colorectal carcinoma relative to normal colorectal (E), and in lung adenocarcinoma relative to normal lung (F). The survival curve comparing the patient with high (red) and low (black) expression in breast cancer (G), brain cancer (H), colorectal cancer (I) and lung cancer (J) was plotted from PrognoScan database as the threshold of cox p-value < 0.05.

doi:10.1371/journal.pone.0155660.g005
Table and expressed as the forest plot (A). The box plot comparing specific ACSL5 expression in normal (left plot) and cancer tissue (right plot) was derived from Oncomine database. The analysis was shown in breast carcinoma relative to normal breast (B), in ovarian carcinoma relative to normal ovary (C), and in lung carcinoma relative to normal lung (D). The statistically significant hazard ratio in various types of cancers was identified from our analyses in S8 Table and expressed as the forest plot (E). The survival curve comparing the patient with high (red) and low
carcinoma and 7 normal breast samples, 2 genes across a panel of 43 ovarian cancer and 10 normal ovary samples, and 111 genes across a panel of 91 lung cancer and 65 normal lung samples were uploaded to the Metacore and the top ten GO Processes were identified (S3D–S3F Fig). The top ranking genes included transmembrane protein 140 (TMEM140), TAP binding protein-like (TAPBPL), baculoviral IAP repeat containing 3 (BIRC3), protein tyrosine phosphatase, receptor type E (PTPRE), and serpin peptidase inhibitor clade B ovalbumin member 1 (SERPINB1). It is interesting to note that PTPRE is coexpressed with ACSL1 and ACSL5 in cancer, which warrants further investigation.

ACSL6

A linkage disequilibrium-based genome-wide association study reveals the role of ACSL6 in premature ovarian failure [67]. The schizophrenia is correlated with the single nucleotide polymorphism of ACSL6 [68]. The meta-analysis uncovers the association between ACSL6 and the number of cigarettes smoked per day. The nicotine-induced ACSL6 upregulation is restored by the nicotine receptor antagonist mecamylamine [69]. The murine long-chain acyl-CoA synthetase (mLACS) regulates the neuronal cell proliferation and differentiation [70]. Analysis from Oncomine revealed that the expression of ACSL6 was down-regulated in leukemia (Fig 7A). In addition, ACSL6 was decreased in most forms of cancers, except colorectal cancer (Fig 7B and S9 Table). The prognostic value of ACSL6 is analyzed using the PrognoScan database with the above threshold (Fig 7C and S10 Table). The better prognosis in leukemia patient was in accordance with the result from Oncomine database (Fig 7D). These data revealed that ACSL6 emerges as a potential tumor suppressor gene in leukemia. The co-expression profiles of ACSL6 were identified from Oncomine (Fig 7E). We identified the co-expression profiles for ACSL6 with a strong cluster of 144 genes across a panel of 1,995 leukemia and 74 normal blood tissues. ACSL6 gene was coexpressed with SRY (sex determining region Y)-box 6 (SOX6), Duffy blood group, chemokine receptor (DARC), and other genes involved in porphyrin-containing compound metabolic processes in leukemia cell (Fig 7F).

Discussion

Increased fatty acid metabolism has been demonstrated to promote tumor progression in several types of cancers. Since ACSL family is required for complex lipid synthesis, the role of ACSL family is suggested to be pro-oncogenic previously [71]. However, the present report indicates that ACSL family members may function as tumor suppressor genes in a variety of cancers with bioinformatics analysis of cancer databases. Combination of the analyses from bioinformatics databases and in vitro analyses, ACSL is a tumor suppressor gene in ovarian and lung cancer and as an oncogene in colorectal cancer (Fig 7G). The analysis of genomic profile reveals that different types of cancers have their own genomic patterns and each cancer possess its biological characteristics. Previous studies demonstrate that ovarian and breast cancers display similar phenotypic and genotypic alterations. The alteration of PTEN and activation of PI3K pathway contribute to cell proliferation and metastasis in ovarian and breast cancer [72,73]. In addition, the breast and ovarian cancers display similar alteration of protein and lipid profiles by MALDI MS analysis [74]. The study assessing the genomic features of ovarian and breast cancer uncovers the similarity of molecular origin, and the dataset comparing the gene expression provides the evidence of similarity between basal-like breast cancer
Fig 7. ACSL6 analysis in various cancer types. (A) The fold change of ACSL6 in various types of cancers was identified from our analyses in Table S9 and expressed as the forest plot. (B) The box plot comparing specific ACSL6 expression in normal (left plot) and cancer tissue (right plot) was derived from Oncomine database. The analysis was shown in acute myeloid leukemia relative to normal blood cell. (C) The statistically significant hazard ratio in various types of cancers was identified from our analyses in Table S10 and expressed as the forest plot. (D) The survival curve comparing the patient with high (red) and low (black) expression in blood cancer was plotted from PrognoScan database as the threshold of cox p-value < 0.05. (E)
and squamous cell lung carcinoma [75,76]. Moreover, the analysis of gene expression predictors of response (GEPR) demonstrates the high similarity between ovarian and lung carcinoma [77]. These evidences support our findings that ACSL may function as a tumor suppressor gene in ovarian and lung cancer. It should be noted that individual ACSL family members have substrate specificity and exert non-overlapping function. ACSL1 may be different from other ACSL family members, and play a pro-oncogenic role in breast cancer as demonstrated by PrognoScan and in vitro analysis. On the other hand, ACSL5 may exert its specific tumor suppressor role in different types of cancer through promoting ceramide [54] or Wnt2B palmitoylation [78,79].

The systematical analysis of lipidomic change shows that fatty acid (FA) and phosphatidylcholines (PC) are increased in various types of cancers and there is a higher ratio of monounsaturated fatty acid (MUFA)/saturated fatty acid (SFA) in breast, lung, colorectal, gastric, and esophageal cancer tissues compared to the adjacent normal tissues. Nevertheless, the ratio of PC(36:1)/PC(36:0) is increased in breast, lung, gastric, and esophageal cancer, but is not altered in colorectal cancer, indicating the cell type-specific metabolic features in colorectal cancer [80]. The network of ACSL1, ACSL4 and steraroyl-CoA desaturase-1 (SCD), which catalyzes the conversion of SFA into MUFA, is demonstrated to induce EMT program and the higher expression level of ACSL1/ACSL4/SCD is associated with the poorer survival outcome in colorectal cancer [81]. These studies describing the potential oncogenic role of ACSL and the differential genomic background in colorectal cancer are in concert with our analyses.

The genomic analysis reveals that different types of cancers have their own genomic patterns and each cancer possess its biological characteristics. Our data indicated that ACSL1 shRNA decreased cell growth and migration in HCT116, but increased cell growth and migration in A549 cells. The ACSL1-coexpressed genes were identified from colorectal and lung cancer datasets respectively. Among the strong cluster of 126 genes in colorectal cancer and 878 genes in lung cancer, only eight genes were co-expressed in both of clusters. In addition, the GO Process demonstrates the diverse effects of ACSL1 on colorectal and lung cancer. It is interesting to note that bioinformatics analysis suggests a potential tumor suppressor role of ACSL family in lung cancer. ACSL is required for conversion of fatty acid into complex lipid or β-oxidation. A report has indicated that PPAR-γ induces anti-proliferation through, at least in part, β-oxidation [82]. Overexpression of ACSL may increase the flux of β-oxidation pathway by PPAR-γ [83]. On the other hand, fatty acid β-oxidation may play an important oncocgenic role in breast cancer [84,85]. These data implies that ACSL1 may behave oppositely when tumor growth has a different metabolic requirement.

In order to have the compelling analysis, we performed the analyses based on a large set of gene expression with clearly defined p-value, fold change and top 10% gene ranking and prognostic outcome with defined p-value and hazard ratio between cancer and normal tissues. With the aim of predicting the potential role of ACSL in cancers, we identified all of the results with statistical significance of gene expression from Oncomine in S1, S3, S5, S7 and S9 Tables and identified all of the results with statistical significance of survival outcome from PrognoScan in S2, S4, S6, S8 and S10 Tables. Most of the analyses predicted the same trend in one cancer. However, a few analyses gave the inconsistent trend in one cancer, including the outcome of ACSL3 in lung cancer of GSE13213 and GSE31210 datasets (Fig 4D and S4 Table), the
expression of ACSL4 in Buchholz and Badea pancreatic cancer datasets (Fig 5A and S5 Table), and the expression of ACSL5 in Hou and Okayama lung cancer datasets (Fig 6A and S7 Table). These datasets were excluded from our analyses, and we defined the potential role of ACSL only based on the consistent analyses of gene expression and outcome. Our approach is less likely to generate the improper or designed data mining and provides the reasonable evaluation with a statistically unbiased assessment.

In summary, bioinformatic analysis with Oncomine and PrognoScan database indicates that ACSL family is involved in the cancer development. The design of inhibitor or activator of ACSL family for cancer therapy is dependent on cancer type since ACSL may play either oncogenic or tumor suppressor role in different types of cancer. In the future, the coexpressed genes with ACSL family identified in this study may be employed to investigate the signal network of ACSL family in cancer or other diseases.

Supporting Information

S1 Fig. Distribution of co-expression profiles and top ten GO processes for ACSL1. ACSL1 was coexpressed with the indicated genes across a panel of 532 breast cancer and 61 normal breast tissues (A), across a panel of 65 rectal adenocarcinoma and 65 normal colorectal tissues (B), and across a panel of 186 lung cancer and 17 normal lung tissues (C). Top 10 significant GO processes were visualized by GeneGo Metacore software according to the co-expression profiles of the 126 genes in colorectal cancer (D) and 878 genes in lung cancer (E). Bar length represented the significance and negative logarithm of enrichment p-value.

S2 Fig. Distribution of co-expression profiles and top ten GO processes for ACSL4. ACSL4 was coexpressed with the indicated genes across a panel of 53 breast carcinoma and 6 normal breast tissues (A), across a panel of 10 brain cancer and 5 normal brain tissues (B), across a panel of 20 colorectal cancer and 20 normal colorectal tissues (C) and across a panel of 25 lung adenocarcinoma and 25 normal lung tissues (D). Top 10 significant GO processes were visualized by GeneGo Metacore software according to the co-expression profiles of the 3,444 genes in breast cancer (E), 117 genes in brain cancer (F), 509 genes in colorectal cancer (G), and 54 genes in lung cancer (H). Bar length represented the significance and negative logarithm of enrichment p-value.

S3 Fig. Distribution of co-expression profiles and top ten GO processes for ACSL5. ACSL5 was coexpressed with the indicated genes across a panel of 40 breast carcinoma and 7 normal breast tissues (A), across a panel of 43 ovarian cancer and 10 normal ovary tissues (B), and across a panel of 91 lung cancer and 65 normal lung tissues (C). Top 10 significant GO processes were visualized by GeneGo Metacore software according to the co-expression profiles of the 3 genes in breast cancer (D), 2 genes in ovarian cancer (E), and 111 genes in lung cancer (F). Bar length represented the significance and negative logarithm of enrichment p-value.

S1 Table. ACSL1 expression in cancers.

S2 Table. The association of ACSL1 expression and the survival in cancer patients.

S3 Table. ACSL3 expression in cancers.
S4 Table. The association of ACSL3 expression and the survival in cancer patients.

S5 Table. ACSL4 expression in cancers.

S6 Table. The association of ACSL4 expression and the survival in cancer patients.

S7 Table. ACSL5 expression in cancers.

S8 Table. The association of ACSL5 expression and the survival in cancer patients.

S9 Table. ACSL6 expression in cancers.

S10 Table. The association of ACSL6 expression and the survival in cancer patients.

S11 Table. The reference lists in supplementary tables.

Acknowledgments

We are grateful to the contributors of data to Oncomine and Prognoscan. The gene ontology analysis was performed using the GeneGo Metacore software provided by the Bioinformatics Core at the National Cheng Kung University, supported by the National Science Council, Taiwan.

Author Contributions

Conceived and designed the experiments: CYW MDL. Performed the experiments: WCC. Analyzed the data: WCC YHH TYW MCY. Wrote the paper: WCC.

References

1. Hu H, Takano N, Xiang L, Gilkes DM, Luo W, Semenza GL. Hypoxia-inducible factors enhance glutamate signaling in cancer cells. Oncotarget 2014; 5: 8853–8868. PMID: 25326682
2. Staubert C, Broom OJ, Nordstrom A. Hydroxycarboxylic acid receptors are essential for breast cancer cells to control their lipid/fatty acid metabolism. Oncotarget 2015; 6: 19706–19720. PMID: 25839160
3. Akimoto M, Iizuka M, Kanematsu R, Yoshida M, Takenaga K. Anticancer Effect of Ginger Extract against Pancreatic Cancer Cells Mainly through Reactive Oxygen Species-Mediated Autotic Cell Death. PLoS One 2015; 10: e0126605. doi:10.1371/journal.pone.0126605 PMID: 25961833
4. Currie E, Schulze A, Zechner R, Walther TC, Farese RV, Jr. Cellular fatty acid metabolism and cancer. Cell Metab 2013; 18: 153–161. doi: 10.1016/j.cmet.2013.05.017 PMID: 23791484
5. Pandey PR, Liu W, Xing F, Fukuda K, Watabe K. Anti-cancer drugs targeting fatty acid synthase (FAS). Recent Pat Anticancer Drug Discov 2012; 7: 185–197. PMID: 22338595
6. Kim S, Lee Y, Koo JS. Differential expression of lipid metabolism-related proteins in different breast cancer subtypes. PLoS One 2015; 10: e0119473. doi: 10.1371/journal.pone.0119473 PMID: 26751270
7. Vargas T, Moreno-Rubio J, Herranz J, Cajas P, Molina S, Gonzalez-Vallinas M, et al. ColoLipidGene: signature of lipid metabolism-related genes to predict prognosis in stage-II colon cancer patients. Oncotarget 2015; 6: 7348–7363. PMID: 26749516
8. Coleman RA, Lewin TM, Muoio DM. Physiological and nutritional regulation of enzymes of triacylglycerol synthesis. Annu Rev Nutr 2000; 20: 77–103. PMID: 10940327
9. Soupene E, Kuypers FA. Mammalian long-chain acyl-CoA synthetases. Exp Biol Med (Maywood) 2008; 233: 507–521.
10. Coleman RA, Lee DP. Enzymes of triacylglycerol synthesis and their regulation. Prog Lipid Res 2004; 43: 134–176. PMID: 14654091
11. Kanter JE, Tang C, Oram JF, Bornfeldt KE. Acyl-CoA synthetase 1 is required for oleate and linoleate mediated inhibition of cholesterol efflux through ATP-binding cassette transporter A1 in macrophages. Biochim Biophys Acta 2012; 1821: 358–364. doi: 10.1016/j.bbalip.2011.10.008 PMID: 22020260
12. Lopes-Marques M, Cunha I, Reis-Henriques MA, Santos MM, Castro LF. Diversity and history of the long-chain acyl-CoA synthetase (Acsl) gene family in vertebrates. BMC Evol Biol 2013; 13: 271. doi: 10.1186/1471-2148-13-271 PMID: 24330521
13. Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. J Biol Chem 1997; 272: 28210–28217. PMID: 9353271
14. Zhou Y, Abidi P, Kim A, Chen W, Huang TT, Kraemer FB, et al. Transcriptional activation of hepatic ACSL3 and ACSL5 by oncostatin m reduces hypertriglyceridemia through enhanced beta-oxidation. Arterioscler Thromb Vasc Biol 2007; 27: 2198–2205. PMID: 17761945
15. Marques RB, Dits NF, Erkens-Schulze S, van Ijcken WF, van Weerden WM, Jenster G. Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines. PLoS One 2011; 6: e23144. doi: 10.1371/journal.pone.0023144 PMID: 21829708
16. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 2007; 9: 166–180. PMID: 17356713
17. Bessarabova M, Ishkin A, JeBailey L, Nikolskaya T, Nikolsky Y. Knowledge-based analysis of proteomics data. BMC Bioinformatics 2012; 13 Suppl 16: S13. doi:10.1186/1471-2105-13-S16-S13 PMID: 23176192
18. Gyorffy B, Surowiak P, Budczies J, Lanczky A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One 2013; 8: e82241. doi: 10.1371/journal.pone.0082241 PMID: 24367507
19. Krammer J, Digel M, Ehehalt F, Stremmel W, Fullekrug J, Ehehalt R. Overexpression of CD36 and acyl-CoA synthetases FATP2, FATP4 and ACSL1 increases fatty acid uptake in human hepatoma cells. Int J Med Sci 2011; 8: 599–614. PMID: 22022213
20. Muir K, Hazim A, He Y, Peyressatre M, Kim DY, Song X, et al. Proteomic and lipidomic signatures of lipid metabolism in NASH-associated hepatocellular carcinoma. Cancer Res 2013; 73: 4722–4731. doi: 10.1158/0008-5472.CAN-12-3797 PMID: 23749645
21. Joseph R, Poschmann J, Sukarieh R, Too PG, Julien SG, Xu F, et al. ACSL1 Is Associated With Fetal Programming of Insulin Sensitivity and Cellular Lipid Content. Mol Endocrinol 2015; 29: 909–920. doi: 10.1210/me.2015-1020 PMID: 25915184
22. Li LO, Grevengoed TJ, Paul DS, Ilkayeva O, Koves TR, Pascual F, et al. Compartmentalized acyl-CoA metabolism in skeletal muscle regulates systemic glucose homeostasis. Diabetes 2015; 64: 23–35. doi: 10.2337/db13-1070 PMID: 25071025
30. Schaffer JE, Lodish HF. Expression cloning and characterization of a novel adipocyte long chain fatty acid transport protein. Cell 1994; 79: 427–436. PMID: 7954810
31. Parkes HA, Preston E, Wilks D, Ballesteros M, Carpenter L, Wood L, et al. Overexpression of acyl-CoA synthetase-1 increases lipid deposition in hepatic (HepG2) cells and rodent liver in vivo. Am J Physiol Endocrinol Metab 2006; 291: E737–744. PMID: 16705061
32. Ellis JM, Mentock SM, Depetris MA, Koves TR, Sen S, Watkins SM, et al. Mouse cardiac acyl coenzyme a synthetase 1 deficiency impairs Fatty Acid oxidation and induces cardiac hypertrophy. Mol Cell Biol 2011; 31: 1252–1262. doi: 10.1128/MCB.01085-10 PMID: 21245374
33. Cui M, Wang Y, Sun B, Xiao Z, Ye L, Zhang X. MiR-205 modulates abnormal lipid metabolism of hepatoma cells via targeting acyl-CoA synthetase long-chain family member 1 (ACSL1) mRNA. Biochem Biophys Res Commun 2014; 444: 270–275. doi: 10.1016/j.bbrc.2014.01.051 PMID: 24462768
34. Poppelreuther M, Rudolph B, Du C, Grossmann R, Becker M, Thiele C, et al. The N-terminal region of acyl-CoA synthetase 3 is essential for both the localization on lipid droplets and the function in fatty acid uptake. J Lipid Res 2012; 53: 888–900. doi: 10.1194/jlr.M024562 PMID: 22357706
35. Fujimoto Y, Itabe H, Sakai J, Makita M, Noda J, Mori M, et al. Identification of major proteins in the lipid droplet-enriched fraction isolated from the human hepatocyte cell line HuH7. Biochim Biophys Acta 2004; 1644: 47–59. PMID: 14741744
36. Fujimoto Y, Itabe H, Kinoshita T, Homma KJ, Onoduka J, Mori M, et al. Involvement of ACSL in local synthesis of neutral lipids in cytoplasmic lipid droplets in human hepatocyte HuH7. J Lipid Res 2007; 48: 1280–1292. PMID: 17379924
37. Yao H, Ye J. Long chain acyl-CoA synthetase 3-mediated phosphatidylcholine synthesis is required for assembly of very low density lipoproteins in human hepatoma HuH7 cells. J Biol Chem 2008; 283: 849–854. PMID: 18003621
38. Kageyama A, Matsui H, Ohta M, Sambuichi K, Kawano H, Notsu T, et al. Palmitic acid induces osteoblastic differentiation in vascular smooth muscle cells through ACSL3 and NF-kappaB, novel targets of eicosapentaenoic acid. PLoS One 2013; 8: e68197. doi: 10.1371/journal.pone.0068197 PMID: 23840832
39. Cao A, Li H, Zhou Y, Wu M, Liu J. Long chain acyl-CoA synthetase-3 is a molecular target for peroxisome proliferator-activated receptor delta in HepG2 hepatoma cells. J Biol Chem 2010; 285: 16664–16674. doi: 10.1074/jbc.M110.112805 PMID: 20308079
40. Weedon-Fekjaer MS, Dalen KT, Solaas K, Staff AC, Duttaroy AK, Nebb HI. Activation of LXR increases acyl-CoA synthetase activity through direct regulation of ACSL3 in human placental trophoblast cells. J Lipid Res 2010; 51: 1886–1896. doi: 10.1194/jlr.M004978 PMID: 20219900
41. Kang MJ, Fujino T, Sasano H, Minekura H, Yabuki N, Nagura H, et al. A novel arachidonate-prefering acyl-CoA synthetase is present in steroidogenic cells of the rat adrenal, ovary, and testis. Proc Natl Acad Sci U S A 1997; 94: 2880–2884. PMID: 9096315
42. Kuch EM, Vellaramkalayil R, Zhang I, Lehnen D, Brugger B, Sreemmel W, et al. Differentially localized acyl-CoA synthetase 4 isoenzymes mediate the metabolic channeling of fatty acids towards phosphatidylinositol. Biochim Biophys Acta 2014; 1841: 227–239. PMID: 24201376
43. Piccini M, Vitelli F, Bruttini M, Pober BR, Jonsson JJ, Villanova M, et al. FACL4, a new gene encoding long-chain acyl-CoA synthetase 4, is deleted in a family with Alport syndrome, elliptocytosis, and mental retardation. Genomics 1998; 47: 350–358. PMID: 9480748
44. Cho YY, Kang MJ, Sone H, Suzuki T, Abe M, Igarashi M, et al. Abnormal uterus with polycysts, accumulation of uterine prostaglandins, and reduced fertility in mice heterozygous for acyl-CoA synthetase 4 deficiency. Biochem Biophys Res Commun 2001; 284: 993–997. PMID: 11409893
45. Cho YY. A novel role of brain-type ACS4 isotype in neuronal differentiation. Biochim Biophys Res Commun 2012; 419: 505–510. doi: 10.1016/j.bbrc.2012.02.046 PMID: 22366036
46. Orlando UD, Garona J, Ripoll GV, Maloberti PM, Solano AR, Avagnina A, et al. The functional interaction between Acyl-CoA synthetase 4, 5-lipoxygenase and cyclooxygenase-2 controls tumor growth: a novel therapeutic target. PLoS One 2012; 7: e40794. doi: 10.1371/journal.pone.0040794 PMID: 22808264
47. Monaco ME, Creighton CJ, Lee P, Zou X, Topham MK, Stafforini DM. Expression of Long-chain Fatty Acyl-CoA Synthetase 4 in Breast and Prostate Cancers Is Associated with Sex Steroid Hormone Receptor Negativity. Transl Oncol 2010; 3: 91–98. PMID: 20360933
48. Cao Y, Pearlman AT, Zimmerman GA, McIntyre TM, Prescott SM. Intracellular unesterified arachidonic acid signals apoptosis. Proc Natl Acad Sci U S A 2000; 97: 11280–11285. PMID: 11005842
49. Cao Y, Dave KB, Doan TP, Prescott SM. Fatty acid CoA ligase 4 is up-regulated in colon adenocarcinoma. Cancer Res 2001; 61: 8429–8434. PMID: 11731423
50. Sung YK, Park MK, Hong SH, Hwang SY, Kim JC, et al. Regulation of cell growth by fatty acid-CoA ligase 4 in human hepatocellular carcinoma cells. Exp Mol Med 2007; 39: 477–482. PMID: 17934335

51. Kan CF, Singh AB, Stafforini DM, Azhar S, Liu J. Arachidonic acid downregulates acyl-CoA synthetase 4 expression by promoting its ubiquitination and proteasomal degradation. J Lipid Res 2014; 55: 1657–1667. PMID: 17934335

52. Cui M, Xiao Z, Sun B, Wang Y, Zheng M, Yw L, et al. Involvement of cholesterol in hepatitis B virus X protein-induced abnormal lipid metabolism of hepatoma cells via up-regulating miR-205-targeted ACSL4. Biochem Biophys Res Commun 2014; 445: 651–655. doi: 10.1016/j.bbrc.2014.02.068 PMID: 24576478

53. Wu X, Li Y, Wang J, Wen X, Marcus MT, Daniels G, et al. Long chain fatty Acyl-CoA synthetase 4 is a biomarker for and mediator of hormone resistance in human breast cancer. PLoS One 2013; 8: e77060. doi: 10.1371/journal.pone.0077060 PMID: 24155918

54. Gassler N, Roth W, Funke B, Schneider A, Herzog F, Tischendorf JJ, et al. Regulation of enterocyte apoptosis by acyl-CoA synthetase 5 splicing. Gastroenterology 2007; 133: 587–598. PMID: 17681178

55. Gassler N, Kopitz J, Tehrani A, Ottenwalder B, Schnolzer M, Kartenbeck J, et al. Expression of acyl-CoA synthetase 5 reflects the state of villus architecture in human small intestine. J Pathol 2004; 202: 188–196. PMID: 14743501

56. Gassler N, Obermuller N, Keith M, Schirmacher P, Autschbach F. Characterization of metaplastic and heterotopic epithelia in the human gastrointestinal tract by the expression pattern of acyl-CoA synthetase 5. Histol Histopathol 2005; 20: 409–414. PMID: 15736044

57. Obermuller N, Keith M, Kopitz J, Autschbach F, Schirmacher P, Gassler N. Coeliac disease is associated with impaired expression of acyl-CoA-synthetase 5. Int J Colorectal Dis 2006; 21: 130–134. PMID: 15809837

58. Klaus C, Kaemmerer E, Reinartz A, Schneider U, Plum P, Jeon MK, et al. TP53 status regulates ACSL5-induced expression of mitochondrial mortalin in enterocytes and colorectal adenocarcinomas. Cell Tissue Res 2014; 357: 267–278. doi: 10.1007/s00441-014-1826-8 PMID: 24770931

59. Pitule P, Vycital O, Bruha J, Novak P, Hosek P, Treska V, et al. Differential expression and prognostic role of selected genes in colorectal cancer patients. Anticancer Res 2013; 33: 4855–4865. PMID: 24222423

60. Gaisa NT, Reinartz A, Schneider U, Klaus C, Heidenreich A, Jakse G, et al. Levels of acyl-coenzyme A synthetase 5 in urothelial cells and corresponding neoplasias reflect cellular differentiation. Histol Histopathol 2013; 28: 353–364. PMID: 23348389

61. Mashek DG, McKenzie MA, Van Horn CG, Coleman RA. Rat long chain acyl-CoA synthetase 5 increases fatty acid uptake and partitioning to cellular triacylglycerol in McArdle-RH7777 cells. J Biol Chem 2006; 281: 945–950. PMID: 16263710

62. Reinartz A, Ehling J, Leue A, Liedtke C, Schneider U, Kopitz J, et al. Lipid-induced up-regulation of human acyl-CoA synthetase 5 promotes hepatocellular apoptosis. Biochim Biophys Acta 2010; 1801: 1025–1035. doi: 10.1016/j.bbala.2010.04.010 PMID: 20470996

63. Bu SY, Mashek DG. Hepatic long-chain acyl-CoA synthetase 5 mediates fatty acid channeling between anabolic and catabolic pathways. J Lipid Res 2010; 51: 3270–3280. doi: 10.1194/jlr.M009407 PMID: 20796351

64. Meller N, Morgan ME, Wong WP, Altemus JB, Sehayek E. Targeting of Acyl-CoA synthetase 5 decreases jejunal fatty acid activation with no effect on dietary long-chain fatty acid absorption. Lipids Health Dis 2013; 12: 88. doi: 10.1186/1476-511X-12-88 PMID: 23767941

65. Teng AC, Adamo K, Tesson F, Stewart AF. Functional characterization of a promoter polymorphism that drives ACSL5 gene expression in skeletal muscle and associates with diet-induced weight loss. FASEB J 2009; 23: 1705–1708. doi: 10.1096/fj.08-120998 PMID: 19218499

66. Mashima T, Sato S, Sugimoto Y, Tsuruo T, Seimiya H. Promotion of glioma cell survival by acyl-CoA synthetase 5 under extracellular acidosis conditions. Oncogene 2009; 28: 9–19. doi: 10.1038/onc.2008.355 PMID: 18806831

67. Kang H, Lee SK, Kim MH, Choi H, Lee SH, Kwack K. Acyl-CoA synthetase long-chain family member 6 is associated with premature ovarian failure. Fertil Steril 2009; 91: 1339–1343. doi: 10.1016/j.fertnstert.2008.03.035 PMID: 18555221

68. Chen X, Wang X, Hossain S, O’Neill FA, Walsh D, Pless L, et al. Haplotypes spanning SPEC2, PDZ-GEF2 and ACSL6 genes are associated with schizophrenia. Hum Mol Genet 2006; 15: 3329–3342. PMID: 17030554
69. Chen J, Brunzell DH, Jackson K, van der Vaart A, Ma JZ, Payne TJ, et al. ACSL6 is associated with the number of cigarettes smoked and its expression is altered by chronic nicotine exposure. PLoS One 2011; 6: e28790. doi: 10.1371/journal.pone.0028790 PMID: 22205969

70. Kee HJ, Koh JT, Yang SY, Lee ZH, Baik YH, Kim KK. A novel murine long-chain acyl-CoA synthetase expressed in brain participates in neuronal cell proliferation. Biochem Biophys Res Commun 2003; 305: 925–933. PMID: 12767919

71. Ellis JM, Frahm JL, Li LO, Coleman RA. Acyl-coenzyme A synthetases in metabolic control. Curr Opin Lipidol 2010; 21: 212–217. PMID: 20480548

72. Mills GB, Lu Y, Fang X, Wang H, Eder A, Mao M, et al. The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Semin Oncol 2001; 28: 125–141. PMID: 11706404

73. Mosleh R, Chu W, Karlan B, Fishman D, Risck H, Fields A, et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 2000; 66: 1259–1272. PMID: 10739756

74. Kang S, Lee A, Park YS, Lee SC, Park SY, Han SY, et al. Alteration in lipid and protein profiles of ovarian cancer: similarity to breast cancer. Int J Gynecol Cancer 2011; 21: 1566–1572. doi: 10.1097/IGC.0b013e318226c5f5 PMID: 22123712

75. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61–70. doi: 10.1038/nature11412 PMID: 23000897

76. Prat A, Adamo B, Fan C, Peg V, Vidal M, Galvan P, et al. Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity. Sci Rep 2013; 3: 3544. doi: 10.1038/srep03544 PMID: 24384914

77. balko JM, Black EP. Ovarian carcinoma as a surrogate tumor for lung adenocarcinomas in evaluating the chemo-stability of a gene expression signature. Cancer Biol Ther 2009; 8: 167–173. PMID: 19029813

78. Klaus C, Schneider U, Hedberg C, Schutz AK, Bernhagen J, Waldmann H, et al. Modulating effects of acyl-CoA synthetase 5-derived mitochondrial Wnt2B palmitoylation on intestinal Wnt activity. World J Gastroenterol 2014; 20: 14855–14864. doi: 10.3748/wjg.v20.i40.14855 PMID: 25356045

79. Yan S, Yang XF, Liu HL, Fu N, Ouyang Y, Qing K. Long-chain acyl-CoA synthetase in fatty acid metabolism involved in liver and other diseases: an update. World J Gastroenterol 2015; 21: 3492–3498. doi: 10.3748/wjg.v21.i12.3492 PMID: 25834313

80. Guo S, Wang Y, Zhou D, Li Z. Significantly increased monounsaturated lipids relative to polyunsaturated lipids in six types of cancer microenvironment are observed by mass spectrometry imaging. Sci Rep 2014; 4: 5959. doi: 10.1038/srep05959 PMID: 25091112

81. Sanchez-Martinez R, Cruz-Gil S, Gomez de Cedron M, Alvarez-Fernandez M, Vargas T, Garcia B, et al. A link between lipid metabolism and epithelial-mesenchymal transition provides a target for colon cancer therapy. Oncotarget 2015; 6: 38719–38736. doi: 10.18632/oncotarget.5340 PMID: 26451612

82. Srivastava N, Kollipara RK, Singh DK, Sudderth J, Hu Z, Nguyen H, et al. Inhibition of cancer cell proliferation by PPARgamma is mediated by a metabolic switch that increases reactive oxygen species levels. Cell Metab 2014; 20: 650–661. doi: 10.1016/j.cmet.2014.08.003 PMID: 25264247

83. Ellis JM, Li LO, Wu PC, Koves TR, Ilkayeva O, Stevens RD, et al. Adipose acyl-CoA synthetase-1 directs fatty acids toward beta-oxidation and is required for cold thermogenesis. Cell Metab 2010; 12: 53–64. doi: 10.1016/j.cmet.2010.05.012 PMID: 20620995

84. Park JH, Vithayathil S, Kumar S, Sung PL, Dobrolecki LE, Putluri V, et al. Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer. Cell Rep 2016; 14: 2154–2165. doi: 10.1016/j.celrep.2016.02.004 PMID: 26923594

85. Pucci S, Zonetti MJ, Fisco T, Polidoro C, Bocchinfuso G, Palleschi A, et al. Carnitine palmitoyl transferase-1A (CPT1A): a new tumor specific target in human breast cancer. Oncotarget 2016.